awmsg logo



ixekizumab (Taltz®)


Reference No. 2051

Excluded date:
28/12/2017


Appraisal information

ixekizumab (Taltz®) 80 mg solution for injection


Company: Eli Lilly & Co Ltd
BNF category: Musculoskeletal and joint diseases
   
   
Submission Type: Unspecified
Status: Excluded

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug therapies

AWMSG advice

Product meets AWMSG exclusion criteria due to NICE appraisal